Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
Related Posts
Wu Y, Meng M, Liu Y, Zeng R, Feng J, Lian Q, Ma Y, Zhang L, Huang W, Leung FW, Duan C, Sha W, Chen[...]
Bunick CG, Armstrong AW, Grada A, Soliman AM, Li C, Bristow CC, Khan IA, Lipiszko D, Silverberg JI, Issa NT, Mostaghimi A. The Epidemiology of[...]
Lapinska S, Pimplaskar A, Shi Z, Ding Y, Frydman-Gani C, Hou K, Venkateswaran V, Boulier K, Olde Loohuis LM, Pasaniuc B. Exploring depression treatment response[...]